The Prostate Cancer Clinical Trials Consortium (PCCTC)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2005
  • Initiating Organization: The Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP)
  • Initiator Type: Nonprofit foundation
  • Disease focus:
    Prostate Cancer
  • Location: North America


The PCCTC has created a new paradigm in collaborative drug development, fostering a culture of transparent project co-development through its unique infrastructure and committed team of research professionals. Its comprehensive suite of contract research organization (CRO) services and world-class scientific expertise streamline and accelerate the activation, accrual, and completion of multicenter clinical trials. The PCCTC is changing how prostate cancer drugs are developed. Their unique infrastructure facilitates project co-development between investigators, clinical research sites, and industry partners.


The PCCTC’s distinguished investigators work together on a single mission: to design, implement, and complete hypothesis-driven early phase trials in prostate cancer, translating scientific discoveries to improved standards of care. They offer services to carry out this mission ensuring efficient trial selection, reporting, site management, clinical operations, and data analyses.

Consortium History

The Prostate Cancer Clinical Trials Consortium (PCCTC) was initiated in 2005 by the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP) in response to critically unmet needs in prostate cancer clinical research identified by physician investigators and patient advocates. To fulfill the mission, it developed a unique infrastructure which has fostered a culture of transparent project co-development between investigators, research sites, and industry partners. Established as an independent entity in 2014, the PCCTC, LLC is now the nation’s premier multicenter clinical research organization specializing in cutting-edge prostate cancer research. Through the collaborative nature and intellectual synergy of their leadership, the PCCTC remains poised to make a significant impact on the lives of patients by keeping the pipeline primed with the most promising novel agents and validated biomarkers.

Structure & Governance

The Consortium is led by a Management Team, a Board of Managers, and a Scientific Oversight Committee.


Funding is provided by the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP).


For current and past news relating to the PCCTC, click here

Points of Contact

Sponsors & Partners

Memorial Sloan Kettering Cancer Center

Dana-Faber/Harvard Cancer Center

Duke Comprehensive Cancer Center

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Oregon Health and Science University Knight Cancer Institute

University of California San Francisco Helen Diller Family Cancer Center

University of Washington Fred Hutchinson Cancer Research Center

University of Wisconsin Carbone Cancer Center

Wayne State University/Karamanos Cancer Institue

UCLA Jonsson Comprehensive Cancer Center

Last Updated: 06/27/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.